Dr Reddy’s Laboratories has acquired a portfolio of 42 abbreviated new drug applications (ANDAs) in the US. Based in Hyderabad, Dr. Reddy’s Laboratories is an Indian multinational pharmaceutical company based in Hyderabad, Telangana, India.
The drug major has entered into a definitive agreement to acquire yet to be marketed portfolio of ANDAs, including more than 30 generic injectable products, the company said in BSE filing. These products will require technology transfers and could be launched in the next one or two years. The value for these products in the US is around $ 645 million for December 2018.
Dr. Reddy’s manufactures and markets a wide range of pharmaceuticals in India and overseas. The company has over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology products
“The acquisition is in line with our stated strategy to significantly enhance our portfolio in our chosen growth markets,” said company’s Chief Executive Officer Erez Israeli.
“This transaction will help augment our injectables product portfolio in the U.S. market and globally,” he added.